Horizon will access a wide range of clinical trial solutions through the Medidata Rave Clinical Cloud platform, to accelerate clinical research through a suite of applications that includes data collection and management, trial design and management
Medidata, from Dassault Systèmes, which develops edge solutions to support the clinical development processes, announced today the expansion of the partnership with .Horizon Therapeutics plc The partnership, which has been ongoing since 2017, has so far included only one technological solution and now, Medidata will provide a diverse package of solutions for Horizon's clinical research needs in many therapeutic areas; Including ophthalmology, rheumatology and nephrology.
"We are pleased to be a key partner to Horizon and its extraordinary journey to help patients by advancing science and treatment pathways," said Tarek Sharif, co-founder and CEO, Medidata. "Medidata's goal is to facilitate Horizon's advancement processes through advanced technologies and analysis tools. We look forward to continuing to further support the company's vision, especially with regard to improving efficiency and shortening the time to complete clinical studies."
Horizon will enter a wide range of clinical trial solutions through Medidata Rave Clinical Cloud, the industry's most widely used platform for accelerating clinical research through a suite of applications that includes data collection and management, trial design and management. In addition, Horizon will use the product Intelligent Trials of Medidata, which applies artificial intelligence (AI) in combination with advanced analysis tools and allows in real time to bring multi-industry performance indicators, build predictive models and make predictions for planning and conducting experiments. Inteligent Trials, powered by Acorn AI, Medidata's data and analytics solutions are built on the broadest set of clinical trials in the industry, serving over six million patients in 22,000+ clinical trials.
"Through the use of Medidata's technologies, we were able to create a more efficient, manageable and cost-effective clinical trial process, which led us to expand this fruitful relationship," said Dr. Karin Rosen, VP of R&D and Chief Scientist at Horizon. "The Medidata platform gives us the flexibility and agility and enables focus and the growth required with the growth and development of our clinical needs."
. Medidata is a wholly owned subsidiary of Dassault Systèmes, which developed the 3DEXPERIENCE platform adapted to the transition of the life sciences field to digital in the era of personalized medicine. It is the first scientific and business platform that provides end-to-end solutions, from research to commercialization.
More of the topic in Hayadan:
